| Autor: |
Juchnicka I; Department of Gynecology and Gynecological Oncology, Medical University of Bialystok, 15-276 Bialystok, Poland., Kuźmicki M; Department of Gynecology and Gynecological Oncology, Medical University of Bialystok, 15-276 Bialystok, Poland., Zabielski P; Department of Medical Biology, Medical University of Bialystok, 15-276 Bialystok, Poland., Krętowski A; Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, 15-276 Bialystok, Poland.; Clinical Research Centre, Medical University of Bialystok, 15-276 Bialystok, Poland., Błachnio-Zabielska A; Department of Hygiene, Epidemiology and Metabolic Disorders, Medical University of Bialystok, 15-276 Bialystok, Poland., Szamatowicz J; Department of Gynecology and Gynecological Oncology, Medical University of Bialystok, 15-276 Bialystok, Poland. |
| Abstrakt: |
We hypothesized that sphingolipids may be early biomarkers of gestational diabetes mellitus (GDM). Here, 520 women with normal fasting plasma glucose levels were recruited in the first trimester and tested with a 75 g oral glucose tolerance test in the 24th-28th week of pregnancy. Serum sphingolipids concentrations were measured in the first and the second trimester by ultra-high performance liquid chromatography coupled with triple quadrupole mass spectrometry (UHPLC/MS/MS) in 53 patients who were diagnosed with GDM, as well as 82 pregnant women with normal glucose tolerance (NGT) and 32 non-pregnant women. In the first trimester, pregnant women showed higher concentrations of C16:0, C18:1, C22:0, C24:1, and C24:0-Cer and lower levels of sphinganine (SPA) and sphingosine-1-phosphate (S1P) compared to non-pregnant women. During pregnancy, we observed significant changes in C16:0, C18:0, C18:1, and C24:1-Cer levels in the GDM group and C18:1 and C24:0-Cer in NGT. The GDM (pre-conversion) and NGT groups in the first trimester differed solely in the levels of C18:1-Cer (AUC = 0.702 p = 0.008), also considering glycemia. Thus, C18:1-Cer revealed its potential as a GDM biomarker. Sphingolipids are known to be a modulator of insulin resistance, and our results indicate that ceramide measurements in early pregnancy may help with GDM screening. |
